Table 1 Correlation between NLRP3 expression and clinicopathological features, IL-1β expression in patients with OSCC (n = 77)
From: NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma
Characteristics | n(77) | NLRP3 expression | P-valuea | ||
|---|---|---|---|---|---|
negative (20) | weak(24) | positive (33) | |||
n(%) | n(%) | n(%) | |||
Age(years) | 0.436 | ||||
≤ 60 | 40 | 10 (25) | 15 (37.5) | 15 (37.5) | |
>60 | 37 | 10 (27) | 9 (24.3) | 18 (48.7) | |
Sex | 0.718 | ||||
Male | 57 | 15 (26.3) | 19 (33.3) | 23 (40.4) | |
Female | 20 | 5 (25) | 5 (25) | 10 (50) | |
Smoking statusb | 0.491 | ||||
Current/former | 36 | 8 (22.2) | 10 (27.8) | 18 (50) | |
Never | 41 | 12 (29.3) | 14 (34.1) | 15 (36.6) | |
Alcohol usec | 0.561 | ||||
Yes | 26 | 5 (19.2) | 8 (30.8) | 13 (50) | |
No | 51 | 15 (29.4) | 16 (31.4) | 20 (39.2) | |
Location | 0.403 | ||||
Gingiva | 23 | 4 (17.4) | 6 (26.1) | 13 (56.5) | |
Tongue | 31 | 11 (35.5) | 11 (35.5) | 9 (29) | |
Floor of mouth | 10 | 1 (10) | 4 (40) | 5 (50) | |
Buccal | 13 | 4 (30.7) | 3 (23.1) | 6 (46.2) | |
AJCC stage | 0.018* | ||||
I | 21 | 10 (47.6) | 8 (38.1) | 3(14.3) | |
II | 41 | 8 (19.5) | 11(26.8) | 22 (53.7) | |
III | 15 | 2 (13.3) | 5 (33.3) | 8 (53.4) | |
T stage | 0.015* | ||||
T1 | 9 | 5 (55.6) | 3 (33.3) | 1 (11.1) | |
T2 | 24 | 10 (43.5) | 6 (26.1) | 8(30.4) | |
T3 | 28 | 3 (10.7) | 10(35.7) | 15 (53.6) | |
T4 | 16 | 2 (12.5) | 5 (31.2) | 9(56.3) | |
N stage | 0.008** | ||||
N0 | 39 | 15(38.5) | 15 (38.5) | 9 (23) | |
N1 | 23 | 3 (13) | 6 (26.1) | 14 (60.9) | |
N2 | 15 | 2 (13.3) | 3 (20) | 10 (66.7) | |
IL-1β expression | 0.004** | ||||
Negative | 21 | 12(57.2) | 4(19) | 5(23.8) | |
Weak | 21 | 4(19) | 7(33.3) | 10(47.7) | |
Positive | 35 | 4(11.4) | 13(37.1) | 18(51.5) | |